News

Pergola breaks down findings from a phase 2 trial of OLC for managing hyperphosphatemia in patients with chronic kidney disease receiving dialysis.

The 2025 Concise Clinical Guidance also aims to assuage vaccine hesitancy and resistance, provide better education, and overcome barriers to implementation.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

Recent research has shown a reduction of nearly 1/3 in type 2 diabetes risk associated with adherence to a Mediterranean diet, calorie reduction, and moderate exercise.

GLP-1 therapies support weight loss, but OSA requires dedicated airway treatment options such as CPAP or neuromuscular stimulation.

Outlook Therapeutics has expressed plans to meet with the FDA to address regulatory issues, as well as expand into European markets.

These findings on teledermatology highlight its effectiveness as a potential solution for disparities in dermatology care within rural communities.

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

The REMS label update reduces the frequency of liver function monitoring and removes the embryo-fetal toxicity monitoring requirement.

These data on roflumilast cream 0.3% highlight the medication’s efficacy and safety in pediatric patients aged 2 - 11 years.

WAO’s updated framework adds mixed N-ERD, mixed NECD, and extends the pediatric term NIUAA to adults.

A trio of experts reflect on unmet needs in gastroparesis, from diagnosis to treatment, and discuss advances that could shape the future of care.

Parent company Iolyx Therapeutics has announced plans to move into phase 3 trials of the investigative immunomodulator later in 2025.

Study highlights risk factors and diagnostic accuracy for immediate-type local anesthetic allergy in children.

This study compared the N-NAIL diagnostic tool to NAPSI, highlighting results among patients with nail psoriasis.

In this video, the last in a 5-part series, panelists discuss their future outlook on bronchiectasis management.

In this video, the fourth in a 5-part series, panelists discuss who may benefit from brensocatib's approval.

In this video, the third in a 5-part series, panelists discuss data from the phase 3 ASPEN trial.

In this video, the second in a 5-part series, panelists discuss the recent FDA approval of brensocatib.

In this video, the first in a 5-part series, panelists discuss recent advancements in bronchiectasis management.

Perceived changes in glucose metabolism and regulation in turn lead to more severe reported menopausal symptoms.

In this analysis, a variety of alternative therapies for hair loss, such as oils, stem cells, and laser treatments, were highlighted for their potential.

People with PBC and pruritus had a greater negative impact on HRQoL and reduced activity compared to those without pruritus, infrequently using medication.

Phase 2 data shows meaning-centered psychotherapy may strengthen psilocybin-assisted therapy for depression in patients with cancer and MDD.

A brief history of intravitreal implants; where we started and how far we can still go to reduce treatment burden for patients and clinicians alike.

This review highlights phase 3 and long-term data on deucravacitinib therapy for patients with plaque psoriasis.

Orforglipron met the primary and all key secondary endpoints in patients with obesity/overweight and type 2 diabetes, supporting global regulatory submissions.